Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kura Oncology Inc KURA

Healthcare Biotechnology
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that... see more

Recent & Breaking News (NDAQ:KURA)

Kura Oncology Reports Second Quarter 2016 Financial Results

GlobeNewswire August 10, 2016

Kura Oncology to Report Second Quarter 2016 Financial Results

GlobeNewswire August 3, 2016

Kura Oncology Doses First Patient in Phase 2 Study of Tipifarnib in Lower Risk Myelodysplastic Syndromes

GlobeNewswire June 16, 2016

Kura Oncology to Participate in the 2016 JMP Life Sciences Conference

GlobeNewswire June 14, 2016

Kura Oncology Entered Agreement With Janssen Pharmaceutica Dated Dec 18, 2014 'to expand the field of the license to all human diseases, disorders or medical conditions'

Benzinga.com  June 6, 2016

Kura Oncology Reports First Quarter 2016 Financial Results

GlobeNewswire May 11, 2016

Intellia Therapeutics Announces Closing of Initial Public Offering

GlobeNewswire May 11, 2016

Kura Oncology Reports Fourth Quarter and Full Year 2015 Operational and Financial Results

GlobeNewswire March 17, 2016

Kura Oncology to Report Fourth Quarter and Full Year 2015 Financial Results

GlobeNewswire March 11, 2016

Kura Oncology to Participate in the Leerink Global Healthcare Conference

GlobeNewswire February 4, 2016

Kura Oncology Announces Data Presentation on Lead Product Candidate Tipifarnib at the Upcoming ASH Meeting

GlobeNewswire December 3, 2015

Kura Oncology to Present at the Oppenheimer 2015 Healthcare Conference

GlobeNewswire December 1, 2015

Kura Oncology to Present at Upcoming Investor Conference

GlobeNewswire November 30, 2015

Kura Oncology Announces First Patient Dosed in an Investigator-Sponsored Phase 2 Trial of Tipifarnib in Patients With HRAS Mutant Urothelial Cancer

GlobeNewswire November 30, 2015

Kura Oncology to Present at the Jefferies 2015 Global Healthcare Conference

GlobeNewswire November 11, 2015

Kura Oncology Announces Launch of Public Offering of Common Stock

GlobeNewswire October 28, 2015

Kura Oncology Appoints Thomas Malley to Board of Directors

GlobeNewswire October 14, 2015

Kura Oncology Initiates Phase 2 Study of Tipifarnib in Peripheral T-cell Lymphoma

GlobeNewswire September 30, 2015

Kura Oncology Cleared for Quotation on the OTCQB

GlobeNewswire September 16, 2015